We use cookies for a better user experience. Read our Privacy Policy

I Agree

Gynecology Drugs Market Insights, 2018-2026

Gynecology Drugs Market (Therapeutics - Hormonal Therapy, Non-Hormonal Therapy; Indication - Gynecology Cancers, Endometriosis, Female Infertility, Menopausal Disorder, Gynecology Infections, Polycystic Ovary Syndrome, Contraception (Birth Control); Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

Global Gynecology Drugs market – Snapshot

Gynecological diseases represent a collective term given to different medical conditions specific to the female reproductive system. Thus, gynecological diseases include conditions affecting the uterus, ovaries and their appendages. Gynecology drugs are the therapeutics utilized for the treatment of various gynecological diseases and symptoms. The global gynecological devices market was valued at US$ 53,376.96 Mn in 2017. It is expected to expand at a CAGR of 5.5% from 2018 to 2026.

In the last decade, the adoption of gynecology drugs has increased owing to the rise in prevalence of gynecological diseases. Change in lifestyle of the global female population has gradually enhanced their healthcare requirements. Consistent rise in awareness about health and well-being has led to an increase in the demand for better gynecological treatments. Sensing this opportunity, various drug manufacturers worldwide have devised more innovative gynecology therapeutics that have better efficacy and minimum side-effects. Furthermore, rising geriatric female population and economic growth are the key factors that are likely to offer lucrative opportunity to the gynecology drugs market.

gynecology-drugs-market.jpg

The global gynecology drugs market has been segmented based on therapeutics, indication, distribution channel, and region. Furthermore, in terms of therapeutics, the market has been divided into hormonal therapy and non-hormonal therapy. The non-hormonal therapy segment is likely to account for a leading share of the global market during the forecast period owing to the effectiveness of the products, rise in adoption of these products, and new product development. Decreasing use of hormonal products due to the risk of breast cancer has boosted the demand for non-hormonal pharmaceutical products. In terms of indication, the market has been classified into gynecology cancers, endometriosis, female infertility, menopausal disorder, gynecology infections, polycystic ovary syndrome, contraception (birth control), and others. In terms of distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is expected to expand at a significant CAGR during forecast period, owing to the convenience of using online pharmacy and rise in number of internet users.

In terms of region, the global gynecology drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the global market in 2017, primarily due to high investments made in cutting-edge drug research, resulting in new, sophisticated treatments with specific mechanism of action; rising emphasis on cancer care, and concentration of some of the world’s major pharmaceutical and biotechnology organizations in the region. The market in Asia Pacific is anticipated to be highly attractive in the near future due to the existence of a large patient pool, increasing awareness coupled with increase in government funding, and developmental initiatives in healthcare facilities in the region. Moreover, low cost of manufacturing in China and India has resulted in the rise in production facilities, attracting key players to the region from across the world. BRICS (Brazil, Russia, India, China, and South Africa) countries are among the fastest-growing economies in the world. According to Siemens Healthineers, health care expenditure in emerging economies increased 11% from 1995 to 2012, which is expected to reach 33% by 2022. Rising population in emerging countries is likely to lead to increased demand for pharmaceutical and biopharmaceutical products in the near future.

Key players operating in the global gynecology drugs market include Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, and Bayer AG. These companies have diverse product offerings and extensive distribution systems across the world. Moreover, entry of small players, especially in emerging markets of Asia, is being witnessed. However, stringent regulatory framework and high-quality standards set by market leaders are anticipated to restrain the penetration of new entrants in the market.

Gynecology Drugs Market - Snapshot

In the last few years, the growth of gynecology drugs has expanded considerably because of the ascent in prevalence of gynecological diseases. Change in way of life of the worldwide female populace has gradually improved their demand for high end medical care necessities. Predictable ascent in mindfulness about wellbeing and prosperity has prompted an expansion in the interest for better gynecological medicines. Detecting this chance, different medication makers worldwide have formulated more imaginative gynecology therapeutics that have better adequacy and least results. Besides, rising geriatric female populace and monetary development are the key factors that are probably going to offer rewarding freedom to the gynecology drugs market.

Gynecologic problems influence the female reproductive system. The most common symptoms of gynecologic problems incorporate pelvic agony, vaginal tingling, vaginal release, strange vaginal dying, and bosom torment and protuberances. The importance and seriousness of these symptoms regularly rely upon age, as these symptoms might be identified with hormonal changes that happen with maturing.

Among other noticeable gynecological diseases, sexually sent illness (STD) is the most common and basic – the most common STD among women is pelvic provocative infection. In the U.S. alone, more than 1,000,000 women suffer from this issue in the course of their life, trailed by chlamydia – a sexually communicated contamination of the vagina, which, whenever left untreated, forms into pelvic incendiary illness. Gynecological problems could possibly be identified with the feminine cycle, which noticeably incorporate feminine issues and endometriosis (strangely found patches of tissue that is ordinarily found distinctly in the covering of the uterus). Moreover, gynecological cancers are additionally common among women all throughout the planet. Endometrial disease and ovarian malignant growth are profoundly common among women. Subsequently, expansion in the prevalence of the conditions referenced above, are probably going to build the take-up of gynecology drugs.

The global gynecology drugs market has been segmented as given below:

Therapeutics

  • Hormonal Therapy
    • Estrogen Therapy
    • Progestin Therapy
    • Combination Therapy
    • Thyroid Replacement Therapy
    • Parathyroid Hormone Therapy
    • Others
  • Non-hormonal Therapy
    • Anti-Infective Agents
    • Anti-neoplastic Agents
    • Anti-inflammatory Agents
    • Others

Indication

  • Gynecology Cancers
  • Endometriosis
  • Female Infertility
  • Menopausal Disorder
  • Gynecology Infections
  • Polycystic Ovary Syndrome
  • Contraception (Birth Control)
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
Gynecology Drugs Market Insights, 2018-2026

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of gynecology drugs market?

The global gynecology drugs market was worth US$ 53.376.96 Mn and is projected to reach a value of US$ 85,833.02 Mn by the end of 2026

What is the anticipated CAGR of the gynecology drugs market in the forecast period?

Gynecology drugs market is anticipated to grow at a CAGR of 5.5% during the forecast period

Which region is expected to project the highest market share in the global gynecology drugs market?

North america accounted for a major share of the global gynecology drugs market

What are the key driving factors for the growth of the gynecology drugs market?

Incidence of menopausal vasomotor symptoms has risen significantly in the last few years, which in turn drives the global gynecology drugs market

Who are the key players in the global gynecology drugs market?

Key players in the global gynecology drugs market include Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, and Bayer AG

1. Preface
   1.1. Report Scope and Market Segmentation
   1.2. Research Highlights

2. Assumptions and Research Methodology
   2.1. Assumptions and Acronyms Used
   2.2. Research Methodology

3. Executive Summary
   3.1. Global Gynecology Drugs Market: Market Snapshot

4. Market Overview
   4.1. Global Gynecology Drugs Market: Product Overview
   4.2. Global Gynecology Drugs Market: Key Industry Developments
   4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
   4.4. Global Gynecology Drugs Market Revenue Projections, 2016–2026
   4.5. Porter’s Five Forces Analysis
   4.6. Global Gynecology Drugs Market Outlook

5. Market Outlook
   5.1. Regulatory Scenario
   5.2. Disease Prevalence
   5.3. Pipeline Analysis

6. Global Gynecology Drugs Market Analysis, by Therapeutics
   6.1. Key Findings
   6.2. Introduction
   6.3. Global Gynecology Drugs Market Value Share, by Therapeutics
   6.4. Global Gynecology Drugs Market Value Forecast, by Therapeutics
        6.4.1. Hormonal Therapy
               6.4.1.1. Estrogen Therapy
               6.4.1.2. Progestin Therapy
               6.4.1.3. Combination Therapy
               6.4.1.4. Thyroid Replacement Therapy
               6.4.1.5. Parathyroid Hormone Therapy
               6.4.1.6. Others
        6.4.2. Non-hormonal Therapy
               6.4.2.1. Anti-Infective Agents
               6.4.2.2. Anti-neoplastic Agents
               6.4.2.3. Anti-inflammatory Agents
               6.4.2.4. Others
   6.5. Global Gynecology Drugs Market Analysis, by Therapeutics
   6.6. Global Gynecology Drugs Market Attractiveness Analysis, by Therapeutics

7. Global Gynecology Drugs Market Analysis, by Indication
   7.1. Key Findings
   7.2. Introduction
   7.3. Global Gynecology Drugs Market Value Share, by Indication
   7.4. Global Gynecology Drugs Market Value Forecast, by Indication
               7.4.1.1. Gynecology Cancers
               7.4.1.2. Endometriosis
               7.4.1.3. Female Infertility
               7.4.1.4. Menopausal Disorder
               7.4.1.5. Gynecology Infections
               7.4.1.6. Polycystic Ovary Syndrome
               7.4.1.7. Contraception (Birth Control)
               7.4.1.8. Others
   7.5. Global Gynecology Drugs Market Analysis, by Indication
   7.6. Global Gynecology Drugs Market Attractiveness Analysis, by Indication

8. Global Gynecology Drugs Market Analysis, by Distribution Channel
   8.1. Key Findings
   8.2. Introduction
   8.3. Global Gynecology Drugs Market Value Share, by Distribution Channel
   8.4. Global Gynecology Drugs Market Value Forecast, by Distribution Channel
        8.4.1. Hospital Pharmacies
        8.4.2. Retail Pharmacies
        8.4.3. Online Pharmacies
   8.5. Global Gynecology Drugs Market Analysis, by Distribution Channel
   8.6. Global Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel

9. Global Gynecology Drugs Market Analysis, by Region
   9.1. Global Gynecology Drugs Market Scenario, by Country
   9.2. Global Gynecology Drugs Market Value Share, by Region
   9.3. Global Gynecology Drugs Market Value Forecast, by Region
        9.3.1. North America
        9.3.2. Europe
        9.3.3. Asia Pacific
        9.3.4. Latin America
        9.3.5. Middle East & Africa
   9.4. Global Gynecology Drugs Market Attractiveness Analysis, by Region

10. North America Gynecology Drugs Market Analysis
   10.1. Key Findings
   10.2. North America Gynecology Drugs Market Overview
   10.3. North America Gynecology Drugs Market Value Share, by Country
   10.4. North America Gynecology Drugs Market Forecast, by Country
        10.4.1. U.S.
        10.4.2. Canada
   10.5. North America Gynecology Drugs Market Value Share Analysis, by Therapeutics
   10.6. North America Gynecology Drugs Market Forecast, by Therapeutics
        10.6.1. Hormonal Therapy
               10.6.1.1. Estrogen Therapy
               10.6.1.2. Progestin Therapy
               10.6.1.3. Combination Therapy
               10.6.1.4. Thyroid Replacement Therapy
               10.6.1.5. Parathyroid Hormone Therapy
               10.6.1.6. Others
        10.6.2. Non-hormonal Therapy
               10.6.2.1. Anti-Infective Agents
               10.6.2.2. Anti-neoplastic Agents
               10.6.2.3. Anti-inflammatory Agents
               10.6.2.4. Others
   10.7. North America Gynecology Drugs Market Value Share Analysis, by Indication
   10.8. North America Gynecology Drugs Market Forecast, by Indication
        10.8.1. Gynecology Cancers
        10.8.2. Endometriosis
        10.8.3. Female Infertility
        10.8.4. Menopausal Disorder
        10.8.5. Gynecology Infections
        10.8.6. Polycystic Ovary Syndrome
        10.8.7. Contraception (Birth Control)
        10.8.8. Others
   10.9. North America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
   10.10. North America Gynecology Drugs Market Forecast, by Distribution Channel
        10.10.1. Hospital Pharmacies
        10.10.2. Retail Pharmacies
        10.10.3. Online Pharmacies
   10.11. North America Gynecology Drugs Market Attractiveness Analysis

11. Europe Gynecology Drugs Market Analysis
   11.1. Key Findings
   11.2. Europe Gynecology Drugs Market Overview
   11.3. Europe Gynecology Drugs Market Value Share, by Country/Sub-region
   11.4. Europe Gynecology Drugs Market Forecast, by Country/Sub-region
        11.4.1. UK
        11.4.2. Germany
        11.4.3. France
        11.4.4. Italy
        11.4.5. Spain
        11.4.6. Rest of Europe
   11.5. Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics
   11.6. Europe Gynecology Drugs Market Forecast, by Therapeutics
        11.6.1. Hormonal Therapy
               11.6.1.1. Estrogen Therapy
               11.6.1.2. Progestin Therapy
               11.6.1.3. Combination Therapy
               11.6.1.4. Thyroid Replacement Therapy
               11.6.1.5. Parathyroid Hormone Therapy
               11.6.1.6. Others
        11.6.2. Non-hormonal Therapy
               11.6.2.1. Anti-Infective Agents
               11.6.2.2. Anti-neoplastic Agents
               11.6.2.3. Anti-inflammatory Agents
               11.6.2.4. Others
   11.7. Europe Gynecology Drugs Market Value Share Analysis, by Indication
   11.8. Europe Gynecology Drugs Market Forecast, by Indication
        11.8.1. Gynecology Cancers
        11.8.2. Endometriosis
        11.8.3. Female Infertility
        11.8.4. Menopausal Disorder
        11.8.5. Gynecology Infections
        11.8.6. Polycystic Ovary Syndrome
        11.8.7. Contraception (Birth Control)
        11.8.8. Others
   11.9. Europe Gynecology Drugs Market Value Share Analysis, by Distribution Channel
   11.10. Europe Gynecology Drugs Market Forecast, by Distribution Channel
        11.10.1. Hospital Pharmacies
        11.10.2. Retail Pharmacies
        11.10.3. Online Pharmacies
   11.11. Europe Gynecology Drugs Market Attractiveness Analysis

12. Asia Pacific Gynecology Drugs Market Analysis
   12.1. Key Findings
   12.2. Asia Pacific Gynecology Drugs Market Overview
   12.3. Asia Pacific Gynecology Drugs Market Value Share, by Country/Sub-region
   12.4. Asia Pacific Gynecology Drugs Market Forecast, by Country/Sub-region
        12.4.1. China
        12.4.2. Japan
        12.4.3. India
        12.4.4. Australia & New Zealand
        12.4.5. Rest of Asia Pacific
   12.5. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics
   12.6. Asia Pacific Gynecology Drugs Market Forecast, by Therapeutics
        12.6.1. Hormonal Therapy
               12.6.1.1. Estrogen Therapy
               12.6.1.2. Progestin Therapy
               12.6.1.3. Combination Therapy
               12.6.1.4. Thyroid Replacement Therapy
               12.6.1.5. Parathyroid Hormone Therapy
               12.6.1.6. Others
        12.6.2. Non-hormonal Therapy
               12.6.2.1. Anti-Infective Agents
               12.6.2.2. Anti-neoplastic Agents
               12.6.2.3. Anti-inflammatory Agents
               12.6.2.4. Others
   12.7. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication
   12.8. Asia Pacific Gynecology Drugs Market Forecast, by Indication
        12.8.1. Gynecology Cancers
        12.8.2. Endometriosis
        12.8.3. Female Infertility
        12.8.4. Menopausal Disorder
        12.8.5. Gynecology Infections
        12.8.6. Polycystic Ovary Syndrome
        12.8.7. Contraception (Birth Control)
        12.8.8. Others
   12.9. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Distribution Channel
   12.10. Asia Pacific Gynecology Drugs Market Forecast, by Distribution Channel
        12.10.1. Hospital Pharmacies
        12.10.2. Retail Pharmacies
        12.10.3. Online Pharmacies
   12.11. Asia Pacific Gynecology Drugs Market Attractiveness Analysis

13. Latin America Gynecology Drugs Market Analysis
   13.1. Key Findings
   13.2. Latin America Gynecology Drugs Market Overview
   13.3. Latin America Gynecology Drugs Market Value Share, by Country/Sub-region
   13.4. Latin America Gynecology Drugs Market Forecast, by Country/Sub-region
        13.4.1. Brazil
        13.4.2. Mexico
        13.4.3. Rest of Latin America
   13.5. Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics
   13.6. Latin America Gynecology Drugs Market Forecast, by Therapeutics
        13.6.1. Hormonal Therapy
               13.6.1.1. Estrogen Therapy
               13.6.1.2. Progestin Therapy
               13.6.1.3. Combination Therapy
               13.6.1.4. Thyroid Replacement Therapy
               13.6.1.5. Parathyroid Hormone Therapy
               13.6.1.6. Others
        13.6.2. Non-hormonal Therapy
               13.6.2.1. Anti-Infective Agents
               13.6.2.2. Anti-neoplastic Agents
               13.6.2.3. Anti-inflammatory Agents
               13.6.2.4. Others
   13.7. Latin America Gynecology Drugs Market Value Share Analysis, by Indication
   13.8. Latin America Gynecology Drugs Market Forecast, by Indication
        13.8.1. Gynecology Cancers
        13.8.2. Endometriosis
        13.8.3. Female Infertility
        13.8.4. Menopausal Disorder
        13.8.5. Gynecology Infections
        13.8.6. Polycystic Ovary Syndrome
        13.8.7. Contraception (Birth Control)
        13.8.8. Others
   13.9. Latin America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
   13.10. Latin America Gynecology Drugs Market Forecast, by Distribution Channel
        13.10.1. Hospital Pharmacies
        13.10.2. Retail Pharmacies
        13.10.3. Online Pharmacies
   13.11. Latin America Gynecology Drugs Market Attractiveness Analysis

14. Middle East & Africa Gynecology Drugs Market Analysis
   14.1. Key Findings
   14.2. Middle East & Africa Gynecology Drugs Market Overview
   14.3. Middle East & Africa Gynecology Drugs Market Value Share, by Country/Sub-region
   14.4. Middle East & Africa Gynecology Drugs Market Forecast, by Country/Sub-region
        14.4.1. GCC
        14.4.2. South Africa
        14.4.3. Rest of MEA
   14.5. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics
   14.6. Middle East & Africa Gynecology Drugs Market Forecast, by Therapeutics
        14.6.1. Hormonal Therapy
               14.6.1.1. Estrogen Therapy
               14.6.1.2. Progestin Therapy
               14.6.1.3. Combination Therapy
               14.6.1.4. Thyroid Replacement Therapy
               14.6.1.5. Parathyroid Hormone Therapy
               14.6.1.6. Others
        14.6.2. Non-hormonal Therapy
               14.6.2.1. Anti-Infective Agents
               14.6.2.2. Anti-neoplastic Agents
               14.6.2.3. Anti-inflammatory Agents
               14.6.2.4. Others
   14.7. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication
   14.8. Middle East & Africa Gynecology Drugs Market Forecast, by Indication
        14.8.1. Gynecology Cancers
        14.8.2. Endometriosis
        14.8.3. Female Infertility
        14.8.4. Menopausal Disorder
        14.8.5. Gynecology Infections
        14.8.6. Polycystic Ovary Syndrome
        14.8.7. Contraception (Birth Control)
        14.8.8. Others
   14.9. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Distribution Channel
   14.10. Middle East & Africa Gynecology Drugs Market Forecast, by Distribution Channel
        14.10.1. Hospital Pharmacies
        14.10.2. Retail Pharmacies
        14.10.3. Online Pharmacies
   14.11. Middle East & Africa Gynecology Drugs Market Attractiveness Analysis

15. Competition Landscape
   15.1. Gynecology Drugs Market Share Analysis, by Company, 2017
   15.2. Competition Matrix
   15.3. Company Profiles
        15.3.1. Allergan plc.
               15.3.1.1. Company Details
               15.3.1.2. Business Overview
               15.3.1.3. Financial Overview
               15.3.1.4. Strategic Overview
               15.3.1.5. SWOT Analysis
        15.3.2. Amgen Inc.
               15.3.2.1. Company Details
               15.3.2.2. Business Overview
               15.3.2.3. Financial Overview
               15.3.2.4. Strategic Overview
               15.3.2.5. SWOT Analysis
        15.3.3. Bayer AG
               15.3.3.1. Company Details
               15.3.3.2. Business Overview
               15.3.3.3. Financial Overview
               15.3.3.4. Strategic Overview
               15.3.3.5. SWOT Analysis
        15.3.4. Merck & Co., Inc.
               15.3.4.1. Company Details
               15.3.4.2. Business Overview
               15.3.4.3. Financial Overview
               15.3.4.4. Strategic Overview
               15.3.4.5. SWOT Analysis
        15.3.5. Pfizer Inc.
               15.3.5.1. Company Details
               15.3.5.2. Business Overview
               15.3.5.3. Financial Overview
               15.3.5.4. Strategic Overview
               15.3.5.5. SWOT Analysis
        15.3.6. Eli Lilly Company
               15.3.6.1. Company Details
               15.3.6.2. Business Overview
               15.3.6.3. Financial Overview
               15.3.6.4. Strategic Overview
               15.3.6.5. SWOT Analysis
        15.3.7. F. Hoffmann-La Roche Ltd.
               15.3.7.1. Company Details
               15.3.7.2. Business Overview
               15.3.7.3. Financial Overview
               15.3.7.4. Strategic Overview
               15.3.7.5. SWOT Analysis
        15.3.8. AstraZeneca
               15.3.8.1. Company Details
               15.3.8.2. Business Overview
               15.3.8.3. Financial Overview
               15.3.8.4. Strategic Overview
               15.3.8.5. SWOT Analysis

List of Tables

Table 01: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 02: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 03: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 04: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 05: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 06: Global Gynecology Drugs Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 07: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Country, 2018–2026
Table 08: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 09: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 10: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 11: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 12: North America Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 14: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 15: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 16: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-Hormonal Therapy, 2016–2026
Table 17: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 18: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 19: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 20: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 21: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 22: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 23: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 24: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 25: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 26: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 27: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 28: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 29: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 30: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 31: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
Table 32: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
Table 33: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Hormonal Therapy, 2016–2026
Table 34: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Non-hormonal Therapy, 2016–2026
Table 35: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Indication, 2018–2026
Table 36: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Gynecology Drugs Market Revenue Projection (US$ Mn), 2016–2026
Figure 02: Global Gynecology Drugs Market Value Share, by Therapeutics, 2018
Figure 03: Global Gynecology Drugs Market Value Share, by Indication, 2018
Figure 04: Global Gynecology Drugs Market Value Share, by Region, 2018
Figure 05: Global Gynecology Drugs Market Value Share, by Distribution Channel, 2018
Figure 06: Global Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 07: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Hormonal Therapy, 2016–2026
Figure 08: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Non-Hormonal Therapy, 2016–2026
Figure 09: Global Gynecology Drugs Market Attractiveness, by Therapeutics, 2018–2026
Figure 10: Global Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 11: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Gynecology Cancers, 2016–2026
Figure 12: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Endometriosis, 2016–2026
Figure 13: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Female Infertility, 2016–2026
Figure 14: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Menopausal Disorder, 2016–2026
Figure 15: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Gynecology Infections, 2016–2026
Figure 16: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Polycystic Ovary Syndrome, 2016–2026
Figure 17: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Contraception (Birth Control), 2016–2026
Figure 18: Global Gynecology Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
Figure 19: Global Gynecology Drugs Market Attractiveness, by Indication
Figure 20: Global Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 21: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 22: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 23: Global Gynecology Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 24: Global Gynecology Drugs Market Attractiveness, by Distribution Channel
Figure 25: Global Gynecology Drugs Market Value Share, by Region, 2018 and 2026 
Figure 26: Global Gynecology Drugs Market Attractiveness, by Region, 2018–2026
Figure 27: North America Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 28: North America Gynecology Drugs Market Attractiveness Analysis, by Country
Figure 29: North America Gynecology Drugs Market Value Share Analysis, by Country, 2018 and 2026
Figure 30: North America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 31: North America Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 32: North America Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 33: North America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 34: North America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 35: North America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 36: Europe Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 37: Europe Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 38: Europe Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 39: Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 40: Europe Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 41: Europe Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 42: Europe Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 43: Europe Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 44: Europe Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 45: Asia Pacific Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 46: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 47: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Country, 2018 and 2026
Figure 48: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 49: Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 50: Asia Pacific Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 51: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 52: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 53: Asia Pacific Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 54: Latin America Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 55: Latin America Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 56: Latin America Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 57: Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 58: Latin America Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 59: Latin America Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 60: Latin America Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 61: Latin America Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 62: Latin America Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 63: Middle East & Africa Gynecology Drugs Market Value (US$ Mn) Forecast, 2018–2026
Figure 64: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 65: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 66: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics, 2018 and 2026
Figure 67: Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication, 2018 and 2026
Figure 68: Middle East & Africa Gynecology Drugs Market Value Share, by Distribution Channel, 2018 and 2026
Figure 69: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Therapeutics, 2018–2026
Figure 70: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Indication, 2018–2026
Figure 71: Middle East & Africa Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 72: Global Gynecology Drugs Market Share Analysis, by Company, 2017 (Estimated)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

823

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved